Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study
Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Cangür, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı · 2024
Read Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study by Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Cangür, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11592548.txt.
Description
A peer-reviewed research article from Europe PMC (2024). (1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin. (2) Methods: A retrospective multicenter study was conducted on patients who were treated with trabectedin for metastatic L-type sarcomas at ten tertiary oncology centers between 2015 and 2023.
Catalog record
| CREATOR | Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Cangür, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |